Evidence map›Paper›PMID 37460908›Full record

ArticleInflammopharmacology2023

Neuromodulatory effect of vardenafil on aluminium chloride/D-galactose induced Alzheimer's disease in rats: emphasis on amyloid-beta, p-tau, PI3K/Akt/p53 pathway, endoplasmic reticulum stress, and cellular senescence.

Heba H Awad, Mahmoud A Desouky, Alaa Zidan, Mariam Bassem, Amaal Qasem, Mona Farouk, Haidy AlDeab, Miral Fouad, Cherry Hany, Nada Basem and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Inflammopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Chemical composition ofFrontiers in pharmacology · 2026
    Article
  14. Frontiers in medicine · 2026
    Article
  15. Article
  16. Article
  17. Coenzyme Q10 alleviates AlClToxicology research · 2025
    Article
  18. Promoting proteostasis by cAMP/PKA and cGMP/PKG.Trends in molecular medicine · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Heba H AwadDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA University), Cairo, Egypt.
Mahmoud A DesoukyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Alaa ZidanDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Mariam BassemDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Amaal QasemDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Mona FaroukDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Haidy AlDeabDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Miral FouadDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Cherry HanyDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Nada BasemDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Rita NaderDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Ashrakat AlkallenyDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Verina RedaDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Mina Y GeorgeDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt. mina.youssif.george@pharma.asu.edu.eg.ORCID http://orcid.org/0000-0003-2887-9937
Ain Shams University · EGOctober University of Modern Sciences and Arts · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysregulation of protein homeostasis, proteostasis, is a distinctive hallmark of many neurodegenerative disorders and aging. Deleteriously, the accumulation of aberrant proteins in Alzheimer's disease (AD) is accompanied with a marked collapse in proteostasis network. The current study explored the potential therapeutic effect of vardenafil (VAR), a phosphodiesterase-5 inhibitor, in AlCl

Indexed as

Alzheimer DiseaseAluminum ChlorideAmyloid beta-PeptidesAnimalsCellular SenescenceGalactosePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsTumor Suppressor Protein p53Vardenafil DihydrochlorideAluminum ChlorideAmyloid beta-PeptidesGalactosePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor Suppressor Protein p53Vardenafil DihydrochlorideAlzheimer’sEndoplasmic reticulum stressPI3K/Akt/p53Proteasome activationSenescenceVardenafil

Identifiers

PMID37460908
PMCPMC10518298
OpenAlexW4384522129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.